Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

Eijiro Yamada; Ting Wen A. Lee; Jeffrey E. Pessin; Claire C. Bastie

doi:10.4155/fmc.10.264

Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

Eijiro Yamada, Ting Wen A. Lee, Jeffrey E. Pessin, Claire C. Bastie

Medicine

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

Original language	English (US)
Pages (from-to)	1785-1796
Number of pages	12
Journal	Future Medicinal Chemistry
Volume	2
Issue number	12
DOIs	https://doi.org/10.4155/fmc.10.264
State	Published - Dec 2010

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.4155/fmc.10.264

Cite this

@article{a0a2a4ad61ff4e0ebd3f48b5eb75dce5,

title = "Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance",

abstract = "Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.",

author = "Eijiro Yamada and Lee, {Ting Wen A.} and Pessin, {Jeffrey E.} and Bastie, {Claire C.}",

year = "2010",

month = dec,

doi = "10.4155/fmc.10.264",

language = "English (US)",

volume = "2",

pages = "1785--1796",

journal = "Future Medicinal Chemistry",

issn = "1756-8919",

publisher = "Future Science",

number = "12",

}

TY - JOUR

T1 - Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

AU - Yamada, Eijiro

AU - Lee, Ting Wen A.

AU - Pessin, Jeffrey E.

AU - Bastie, Claire C.

PY - 2010/12

Y1 - 2010/12

N2 - Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

AB - Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic -cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

UR - http://www.scopus.com/inward/record.url?scp=78650217374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650217374&partnerID=8YFLogxK

U2 - 10.4155/fmc.10.264

DO - 10.4155/fmc.10.264

M3 - Review article

C2 - 21428801

AN - SCOPUS:78650217374

VL - 2

SP - 1785

EP - 1796

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 12

ER -

Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this